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Summan, A total of 63 patients with colorectal cancer were studied for proliferativ.e activity bv an immunohistochemical technique using a monoclonal antibody against DNA polymerase The DNA
polyrmerase positive cell rates ranged from 24.0% to 74.60/0. There was a correlation betuween the DNA polvmerase a positive cell rates of biopsies and resected specimens. There was no significant correlation between DNA polymerase a positive cell rates and histological type. tumour size. invasion of bowel wall. Iymphatic invasion. venous invasion. Iymph node metastasis or peritoneal metastasis. Tumours With a high growth fraction (a DNA polymerase positive cell rate > 420o) were more frequentlv associated With liver
metastasis than those with a lo- growth fraction (a DNA polymerase a positive cell rate <420o). Patients with high growth fraction tumours had significantl poorer prognoses than those with low growth fraction
tumours. The results of multivanate analysis using the proportional hazard model of Cox indicated that the DNA polvmerase positive cell rates. liver metastasis, and peritoneal metastasis were independent prognostic factors. The results indicate that the DNA polymerase positive cell rate mav be a useful prognostic marker of colorectal cancers.
The proliferative activity of tumours has been found to
correlate with clinical prognosis. It is important therefore to
know the proliferative activity of a tumour in choosing an
adequate therapeutic method and predicting the prognosis of
the disease. To know the growth fraction of cancers. various
techniques. including the 3H-thymidine labelling index
(Bleiberg & Galana. 1976: Sasaki. 1977). BrdU labelling
index (Gratzner. 1982). flow cytometric analysis (Barlogie et
al.. 1983: Shutte et al.. 1987: Volm et al.. 1988). Ki-67
positive rate (Gerdes et al.. 1983: 1984) and DNA
polvmerase x positive cell rate have been used.
DNA polymerase a. the most important enzyme in DNA
replication (Sarngadharan et al.. 1978: Weissbach. 1979). is
localized in the nucleus of proliferative cells in the GI. S. and
G, phase and in the cytoplasm in the M phase (Bensch et al..
1982: Matsukage et at.. 1983). DNA polymerase a. therefore.
enables the immunohistochemical detection of cycling cells
without the need for external administration of H-thvmidine
or BrdU. We previously reported that the determination of
growth fractions with a monoclonal antibody to DNA
poly'merase a would be a useful prognostic marker of
colorectal cancers (Yamaguchi et al.. 1990). For better
comprehension of the biological behaviour of tumours with
colorectal cancers. we studied cell kinetics bv use of a mono-
clonal antibody against DNA polymerase a and compared
the DNA polymerase a positive cell rates of biopsy and
resected specimens obtained from colorectal cancers.
Materials and methods
Patients and tissue sample
Sixty-three patients with primary colorectal cancers diag-
nosed and treated in the Department of Surgery II
Kanazawa University. between 1986 and 1989. were entered
in the study. Sixty-three lesions of colorectal cancer from 13
specimens obtained by endoscopic biopsy and 63 specimens
by surgical resection were studied for cell kinetics by use of a
monoclonal antibody against DNA polymerase a. The 63
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tumours comprised 36 lesions of colon and 27 lesions of
rectal cancers. Twenty-nine (46.0%) of the 63 patients were
positive for lymph node metastases. 15 (23.80o). positive for
hepatic metastases. and four (6.30 o). positive for peritoneal
metastases. Twelve of the patients were dead from their
diseases between 5 months and 3 years after resection.
Immunohistochemical stainingprocedure
The tumour tissues from biopsy or resected specimens were
snap-frozen. and sliced into 6pm thick sections. After air-
drving, the sections were fixed with 400 paraformaldehvde
for 30 mmn at 4°C. They were washed with phosphate- buffered saline (PBS). pH 7.2 for 5 min. and then incubated
with a 1:50 dilution of a DNA polymerase a antibody
(CL22-2-42B.MBL) at room temperature overnight. The
primanr antibody was produced by Masaki et al. (1982).
Non-immune mouse serum was substituted for primary
antibody on each section to serve as a negative control. After
washing in PBS. sections were covered with a 1:30 dilution of
biotinylated goat antimouse IgG (Tago, Burlingam. CA) at
room temperature for 30 min. They were finally incubated
with an avidin-biotinylated horseradish peroxidase complex (ABC) (Vector Laboratories. Burlingame. CA). The antibody
was located by reaction with 3-3'-diaminobenzene tetra-
hydrochloride (DAB). (Dotide, Tokyo. Japan) and H2O, in
0.05 mM Tris buffer. pH 7.2. The slides were lightly counter-
stained with methyl green for 30 min. DNA polymerase a
positive cells exhibited the deposition of brown DAB
precipitate. The stained cells per approximately 1.000 tumour
cells were counted in each of 10 microscopic fields using a
standard light microscope equipped with an ocular reticle.
Areas of the section with clear DNA polymerase a positive cells were used for counting. and areas with poor immuno-
staining for DNA polymerase a were neglected.
Statisticalanaltsis
Data are presented as the mean ± standard deviation of the
mean. Statistical analysis was performed by the ,2 test. The
outcomes in different groups of patients were compared by
the generalised Wilcoxon test. Using the proportional
hazards model of Cox. multivariate analysis was performed
on the factors said to affect the prognosis in patients with
colorectal cancer. The cut-off point for low or high growth
fraction was determined by the analysis of a Cox model.
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Results
Immunohistochemicallv stained monoclonal antibody against
DNA polymerase a was distributed in tumour cell nuclei
(Figure 1). There are no tumour cells with cytoplasmic stain-
ing. The rates of DNA polymerase a positive cells for the 63
resected specimens ranged from 24.0% to 74.60/O (mean
4488%: SD 9.4%). The DNA polymerase a positive cell rates
of biopsy and resected specimens taken from the same
tumours were compared. An intimate correlation was found
between the two kinds of specimens from 13 of the patients
(r = 0.872. P <0.001) (Figure 2).
To find the grade of malignancy. the tumours were divided
into two groups by the DNA polymerase a positive cell rates.
Tumours with a DNA polymerase a positive cell rate of
>42% were designated as high growth fraction. and those
with a DNA polymerase a positive cell rate of <42%. as low
growth fraction. There was no significant correlation between
the DNA polymerases a positive cell rates and the histo-
logical type. tumour size. invasion of bowel wall. lymphatic
invasion. venous invasion. lymph node metastases. or
peritoneal metastasis (Table I). Liver metastases were observ-
ed in 11 (34.400) of 32 patients with high growth fraction
tumours. and four (12.9%) of 31 with low growth fraction
tumours (Table I). There was a significant difference in liver
metastases between the twso groups of patients (P <0.05).
During the follow-up period of 1-4 vears. 10 (31.300)
patients with high grow-th fraction tumours died of their
disease. compared with two (6.50°) of patients with low
growth fraction tumours. Figure 3 depicts the Kaplan-Meier
curves for the survival of these two groups. The correlation
between the DNA polymerase x positive cell rates and the
prognosis indicated that the patients with high growth frac-
tion tumours had a significantly poorer prognosis than those
with low growth fraction tumours (P <0.05). The unirvariate
analysis revealed a correlation between the prognotic and the
tumour size. serosal invasion. venous invasion. lymph node
metastases. hepatic metastases. peritoneal metastases and
DNA poolymerase a positive cell rates. In addition. the prog-
nosis factors in 63 patients with colorectal cancers were
examined according to the proportional hazard model of
Cox. The results showed that the DNA polymerase a positive
cell rate had the greatest value of all prognostic factors.
followed by the liver metastases and peritoneal metastases.
However. the tumour size. venous invasion. and lymph node
metastasis were of little independent prognostic value.
Discussion
DNA polymerase a is known to be present in the nucleus of
proliferative cells in the G1. S and G. phases among trans-
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DNA polymerase ca positive cells rates
of biopsy specimens
Figure 2 Scattergram shoWing the correlation betu-een DNA
polymerase m positive cell rates of endoscopic biopsy and those of
resected specimens. There is good correlation betseen the DNA
polvmerase m positive cells rates obained by both methods.
Table I Correlation of DNa polvmerase m positise cell rates and
climicopathological findings
D.NA polvmerase m positive cells rate
<4200 42 o
Histological type
well differentiated 18 14 NS
moderatels differentiated 13 18
Tumour size
<5cm 14 12 NS
5cm 17 20
Serosal insasion
negative 24 23 NS
positive 7 9
Lymphatic insasion
negative 9 14 NS
positive 2 18
Venous invasion
negative 23 18 NS
positive 8 14
Lymph node metastasis
negative 16 18 NS
positive 15 14
Hepatic metastasis
negative 27 21 P <0.05
positive 4 11
Pen'toneal metastasis
negative 31 28 NS
positive 0 4
Figue I Immunohistochemical staining with monoclonal anti-
body against DNA polymerase c. DNA polymerase x positive
cells were found throughout the cancer nest (x 400).
bution in the M phase of the cell cycle (Bensch et al.. 1982:
Matsukage et al., 1983; Nakamura et al.. 1984). Monoclonal
antibody against DNA polymerase a recognises a nuclear
antigen that is expressed in cycling cells but does not react
with the cells in the Go phase. It has been known that the
monoclonal antibody against DNA polymerase a positive
cells is suitable for detecting the proliferative activity in
tumours. It has also been reported that DNA polymerase a
was detected by use of this monoclonal antibody in uterine
tumours and colorectal cancers (Mushika et al., 1988; Yama-
guchi et al.. 1990). We previously reported that while the
average DNA polymerase a positive cell rate was 24.5% for
seven patients with benign colorectal adenoma. it was 44.2%
o/o
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DNA polymerase ot positive cells rate < 42%
_-- (n = 31)




Fgure 3 Survival curves of patients with colorectal cancer. sub-
divided according to the DNA polymerase cx positive cell rate.
for colorectal cancer patients (Yamaguchi et al.. 1990). In
this study. we have examined the relation between the pro-
liferative activity determined by use of the monoclonal
antibody against DNA poly-merase x and the clinical out-
come of colorectal cancer patients.
The prognosis of cancer patients is largely determined by
tumour mass stage. grade of malignancy. and host immunity.
The grade of malignancy depends on the proliferative activity
and metastatic potential of tumours. Recent reports argue
that tumours with high proliferative activity have a poorer
prognosis than those with low proliferative rates (Tribubait
et al.. 1983: Sledge et al.. 1988: Yonemura et al.. 1988:
Yonemura et al.. 1990a).
Lelle et al. (1987) argue that among 154 patients with
breast cancer they examined. the proliferative activity deter-
mined using monoclonal antibodv Ki-67 was significantly
higher for ly-mph node-positive patients than for node-
negative ones and. further. that this antibody is useful in
predicting the prognosis and choosing an adequate
therapeutic modality. Yonemura et al. (1990b) studied the
proliferative activity in gastric cancer using Ki-67 mono-
clonal antibody and reported that the patients with high
proliferative activity died significantly earlier than those with
lower proliferative activity. In this study. we divided the
tumours into two groups by DNA polymerase a positive cell
rate and examined the relation between proliferative activits
and the cinicopathologic features. Immunohistochemical
staining with monoclonal antibody against DNA polymerase
a offers a sensitive. simple. and objective technique for detec-
tion of grow-th fraction. However. DNA polyrmerase a
immunoreactivity can be detected in only fresh material fixed
in PLP or PFA. So. tissue samples should be frozen immedi-
ately and stored at - 70C. There was no correlation
between the growth fractions of tumours and histological
type. invasion of bowel wall. lymphatic invasion. venous
invasion or lymph node metastases. However, we found a
correlation between the proliferative activity determined with
the monoclonal antibody against DNA polymerase a and
liver metastases. This finding indicated that the determination
ofgrowth fraction by use of the monoclonal antibody against
DNA polymerase a may be useful in judging the existence of
liver metastasis of colorectal cancers.
DNA polymerase a positive cell rates were in close corre-
lation with the prognosis of colorectal cancers. The prognosis
was poor in colorectal cancer patients with high DNA poly-
merase a positive cell rate, whereas those with low DNA
polymerase a positive cell rates have favourable prognosis.
Colorectal cancer patients with high growth fraction tumours
died significantly earlier than those with low growth fraction
tumours. The univariate analysis revealed a correlation
between the prognosis and the tumour size. venous invasion.
lymph node metastasis, hepatic metastasis, peritoneal metas-
tasis. and DNA polymerase a positive cells rates. However.
the results of multivariate analysis using the proportional
hazards model of Cox also indicated that the DNA
polymerase a positive cell rate. hepatic metastasis. and
peritoneal metastasis emerged as independent prognostic fac-
tors. Growth fraction was the most valuable indicator of
prognosis (Table II).
In other words. it is important to know the proliferative
activity pre-operatively in choosing an adequate therapeutic
method and predicting the prognosis. We tried to compare
the growth fractions of biopsy and resected specimens by use
of a monoclonal antibody against DNA polymerase a. There
is a good correlation between the DNA polymerase a positive
cell rates of the two groups. Regarding intratumoural
heterogeneity of growth fraction, it is possible to avoid over-
looking small clones of tumour cells by taking several biopsy
specimens from separate areas. We therefore came to the
conclusion that it would be possible to analyse pre-
operatively the proliferative activity detected in several
biopsy specimens by use of a monoclonal antibody against
DNA polymerase a.
From the findings, it may be concluded that the detection
of growth fraction by use of a monoclonal antibody against
DNA polymerase x pre-operatively enables the measurement
of proliferative activity in biopsy specimens. and that the
growth fraction of colorectal tumours is a useful indicator in
projecting the prognosis. Tumours with a high growth frac-
tion run poor prognoses and it is advisable. therefore. to
perform intensive postoperative therapy for such tumours
because the chemosensitivity of tumours is related to the
ratio of proliferating cells.
Table II Vanrables of independent prognosis importance in 63 patients with colorectal
cancer
Lnivariate analysis Multivariate analysis
Prognostic variable Z *alue P value F value P value
Histological type 0.907 0.365 0.284 0.596
(well moderate1v diff.)
Tumour size 2.074 0.038 0.358 0.552
(<5 cm 5cm)
Serosal invasion 2.491 0.013 1.085 0.302
(negative positive)
Lymphatic invasion 0.4886 0.625 0.670 0.417
(negative positive)
Venous invasion 2.660 0.007 2.477 0.122
(negative positive)
Lymph node metastasis 2.717 0.007 3.053 0.086
(negative positive)
Hepatic metastasis 5.105 0.000 5.334 0.025
(negative positive)
Peritoneal metastasis 2.188 0.029 4.230 0.045
(negative positive)
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